Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Convertible Debt (2017 - 2023)

Neurocrine Biosciences (NBIX) has disclosed Convertible Debt for 6 consecutive years, with $169.5 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Convertible Debt changed N/A year-over-year to $169.5 million, compared with a TTM value of $169.5 million through Mar 2023, changed N/A, and an annual FY2020 reading of $317.9 million, changed N/A over the prior year.
  • Convertible Debt was $169.5 million for Q1 2023 at Neurocrine Biosciences, down from $330.7 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $414.1 million in Q1 2020 and bottomed at $169.5 million in Q1 2023.
  • Average Convertible Debt over 4 years is $341.8 million, with a median of $330.7 million recorded in 2021.
  • The sharpest move saw Convertible Debt increased 5.25% in 2020, then decreased 22.24% in 2021.
  • Year by year, Convertible Debt stood at $403.6 million in 2019, then decreased by 21.23% to $317.9 million in 2020, then rose by 4.03% to $330.7 million in 2021, then crashed by 48.75% to $169.5 million in 2023.
  • Business Quant data shows Convertible Debt for NBIX at $169.5 million in Q1 2023, $330.7 million in Q3 2021, and $326.3 million in Q2 2021.